Edgar Filing: Akers Biosciences Inc - Form 4

Akers Biosci Form 4 June 14, 201											
FORM	-	OMB APPROVAL									
	UNITED		ashington			NGE C	COMMISSION	OMB Number:	3235-0287		
Check the	ter							Expires:	January 31,		
if no longer subject to STATEMENT OF CHAN				GES IN BENEFICIAL OWNERSHIP				Estimated a	2005 average		
Section 16. Form 4 or				SECURITIES				burden hours per response 0			
Form 5	Filed purs	suant to Section	16(a) of th	response 6(a) of the Securities Exchange Act of 1934,							
obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section											
See Instruction 30(h) of the Investment Company Act of 1940											
1(b).											
(Print or Type Responses)											
1. Name and Address of Reporting Person *2. IssuerGormally John JSymbol				uer Name and Ticker or Trading 5. Relationship of Reporting Person(s) to Issuer					son(s) to		
		-	s Biosciences Inc [AKER]				(Check all applicable)				
(Last)					Earliest Transaction			(Check all applicable)			
			Day/Year)			Director 10% Owner X Officer (give title Other (specify					
80 WALSH DRIVE 06/08/2			2016				below) below) Chief Executive Officer				
			mendment, Date Original			6. Individual or Joint/Group Filing(Check					
			Ionth/Day/Year)				Applicable Line)				
MAHWAH, NJ 07430				_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(State) ((Zip) Ta	ble I - Non-I	Derivative S	Securit	ies Aca	uired, Disposed of	° or Beneficial	lv Owned		
1.Title of	2. Transaction Date		3.			-	5. Amount of	6. Ownership	•		
Security	(Month/Day/Year)		ate, if Transaction(A) or Disposed of (D)				Securities	Form: Direct	Indirect		
(Instr. 3)		any (Month/Day/Year	Code (Instr. 3, 4 and 5) /Day/Year) (Instr. 8)			Beneficially Owned	(D) or Indirect (I)	Beneficial Ownership			
		``` <b>`</b>	, , ,				Following	(Instr. 4)	(Instr. 4)		
					(A)		Reported Transaction(s)				
			Code V		or (D)	Price	(Instr. 3 and 4)				
Common Stock	06/08/2016		G	27,500 (1)	А	\$ 1.99	30,000	D			
20001				_		1.77					

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact: Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	Date	Amou Unde Secur	le and int of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: Akers Biosciences Inc - Form 4

## **Reporting Owners**

Reporting Owner Name / Addre	ddress Relationships						
	Director	10% Owner	Officer	Other			
Gormally John J 80 WALSH DRIVE MAHWAH, NJ 07430			Chief Executive Officer				
Signatures							
/s/ John J. Gormally	06/14/2016						
<u>**</u> Signature of Reporting Person	Date						

## **Explanation of Responses:**

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On June 8, 2016 Mr. Gormally was issued 27,500 shares of common stock (the "Shares") under the Company's 2013 Incentive Stock and Award Plan, as amended. Pursuant to the Restricted Stock Agreement between Mr. Gormally and the Company governing the issuance of the Shares, 9,167 of the Shares vested on June 8, 2016, 9,167 of the Shares will vest on March 1, 2017, and 9,166 of the Shares will vest on March 1, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.